| Congenital agammaglobulinemia
Bivigam vs Privigen
Side-by-side clinical, coverage, and cost comparison for congenital agammaglobulinemia.Deep comparison between: Bivigam vs Privigen with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsPrivigen has a higher rate of injection site reactions vs Bivigam based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Privigen but not Bivigam, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Bivigam
Privigen
At A Glance
IV infusion
Every 3-4 weeks
Intravenous immune globulin (IVIG)
IV infusion
Every 3-4 weeks
Intravenous immunoglobulin (IVIG)
Indications
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Congenital agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
- Congenital agammaglobulinemia
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
- Immune thrombocytopenic purpura
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Dosing
Common Variable Immunodeficiency, X-linked agammaglobulinemia, Congenital agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency 300 to 800 mg/kg IV every 3 to 4 weeks; initial infusion rate 0.5 mg/kg/min, increase every 20 minutes if tolerated up to 6 mg/kg/min; adjust dose to maintain trough IgG >= 600 mg/dL.
Congenital agammaglobulinemia, Common Variable Immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency 200-800 mg/kg IV every 3-4 weeks.
Immune thrombocytopenic purpura 1 g/kg IV daily for 2 consecutive days (total dose 2 g/kg).
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Loading dose: 2 g/kg IV in divided doses over 2-5 consecutive days; maintenance dose: 1 g/kg IV every 3 weeks.
Contraindications
- Previous anaphylactic or severe systemic reaction to human immune globulin
- IgA deficiency with antibodies to IgA and a history of hypersensitivity
- History of anaphylactic or severe systemic reaction to human immune globulin
- Hyperprolinemia (product contains L-proline stabilizer)
- IgA deficiency with antibodies to IgA and a history of hypersensitivity
Adverse Reactions
Most common (>=5%) Headache, fatigue, infusion site reaction, nausea, sinusitis, blood pressure increased, diarrhea, dizziness, lethargy
Serious Vomiting, dehydration
Postmarketing Apnea, ARDS, TRALI, cyanosis, hypoxemia, pulmonary edema, dyspnea, bronchospasm, cardiac arrest, thromboembolism, vascular collapse, hypotension, coma, loss of consciousness, seizures, tremor, Stevens-Johnson syndrome, epidermolysis, erythema multiforme, bullous dermatitis, pancytopenia, leukopenia, hemolysis, positive direct antiglobulin test, pyrexia, rigors, back pain, hepatic dysfunction, abdominal pain
Most common (>5%) Headache, fatigue, nausea, chills, vomiting, back pain, elevated body temperature, diarrhea, cough, stomach discomfort, asthenia, hypertension, pain in extremity, hemolysis, anemia, leukopenia, rash
Serious Hypersensitivity, aseptic meningitis syndrome, hemolysis, renal dysfunction and acute renal failure, thrombosis, hyperproteinemia, hyponatremia, volume overload, transfusion-related acute lung injury
Postmarketing Decreased neutrophil count, hemoglobinuria, renal failure, photophobia, cerebral edema, pruritus, cardiac arrest, thromboembolism, Stevens-Johnson syndrome, ARDS, seizures, hepatic dysfunction
Pharmacology
BIVIGAM is an intravenous IgG replacement therapy that provides a broad spectrum of neutralizing antibodies against bacterial and viral pathogens and their toxins; IgG antibodies act as opsonins, enhancing phagocytosis and elimination of pathogens from the circulation.
PRIVIGEN is an intravenous immunoglobulin that supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against a wide variety of bacterial and viral agents; the mechanism of action has not been fully elucidated but may include immunomodulatory effects.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Bivigam
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Privigen
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (0/12)
UnitedHealthcare
Bivigam
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Privigen
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (0/8)
Humana
Bivigam
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Privigen
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Privigen.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BivigamView full Bivigam profile
PrivigenView full Privigen profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.